Company / EPS (Basic)
ENANTA PHARMACEUTICALS INC EPS (Basic) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$6.38
FY2025
5-year range
-$6.38 / $2.37
FY2021-FY2025
Trend
-8.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Basic) has declined for 5 consecutive years, from $3.74 in FY2020 to $-6.38 in FY2025.
Based on SEC 10-K filings.
-6.38 in FY2025.
Declined from $-3.92 to $-6.38 over the past 2 years.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's eps (basic) has declined for 5 consecutive years.
- In FY2025, eps (basic) decreased 8.0% year-over-year.
- Peak eps (basic) was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$6.38 | -8.0% |
| FY2024 | -$5.91 | -50.8% |
| FY2023 | -$3.92 | -116.6% |
| FY2022 | -$1.81 | -176.4% |
| FY2021 | $2.37 | -36.6% |
| FY2020 | $3.74 | +302.2% |
| FY2019 | $0.93 | -18.4% |
| FY2018 | $1.14 | -73.0% |
| FY2017 | $4.23 | +125.0% |
| FY2016 | $1.88 | +380.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026